New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
AI-based model can predict therapy outcome in ovarian cancer patients

AI-based model can predict therapy outcome in ovarian cancer patients

Nov 13 2023Universita Cattolica del Sacro CuoreA model based on artificial intelligence is able to predict the therapy outcome (measured by volumetric reduction of tumor lesions) in 80% of ovarian can
World medicine November 24,2023
AI-based model can predict therapy outcome in ovarian cancer patients

AI-based model can predict therapy outcome in ovarian cancer patients

Nov 13 2023Universita Cattolica del Sacro CuoreA model based on artificial intelligence is able to predict the therapy outcome (measured by volumetric reduction of tumor lesions) in 80% of ovarian can
World medicine November 24,2023
RNA-based molecular subtypes can help predict response to chemotherapy in muscle-invasive bladder cancer

RNA-based molecular subtypes can help predict response to chemotherapy in muscle-invasive bladder cancer

Nov 15 2023SWOG Cancer Research NetworkRNA-based molecular subtypes modestly improved predictions for pathologic downstaging in muscle-invasive bladder cancer. Results point to the possibility of futu
World medicine November 24,2023
RNA-based molecular subtypes can help predict response to chemotherapy in muscle-invasive bladder cancer

RNA-based molecular subtypes can help predict response to chemotherapy in muscle-invasive bladder cancer

Nov 15 2023SWOG Cancer Research NetworkRNA-based molecular subtypes modestly improved predictions for pathologic downstaging in muscle-invasive bladder cancer. Results point to the possibility of futu
World medicine November 24,2023
Engineering approach reveals surprising macrophage phenotype with best tumor-targeting ability

Engineering approach reveals surprising macrophage phenotype with best tumor-targeting ability

Nov 15 2023Harvard John A. Paulson School of Engineering and Applied SciencesMacrophages, a type of white blood cell that can destroy invading pathogens, have an innate ability to infiltrate tumor cel
World medicine November 24,2023
Engineering approach reveals surprising macrophage phenotype with best tumor-targeting ability

Engineering approach reveals surprising macrophage phenotype with best tumor-targeting ability

Nov 15 2023Harvard John A. Paulson School of Engineering and Applied SciencesMacrophages, a type of white blood cell that can destroy invading pathogens, have an innate ability to infiltrate tumor cel
World medicine November 24,2023
Immune response that protects against infections also drives HIV latency

Immune response that protects against infections also drives HIV latency

Nov 15 2023Duke HealthAn immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, lurking in cells o
World medicine November 24,2023
Immune response that protects against infections also drives HIV latency

Immune response that protects against infections also drives HIV latency

Nov 15 2023Duke HealthAn immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, lurking in cells o
World medicine November 24,2023
Scientists develop an improved method to study Parkinson's disease in the lab

Scientists develop an improved method to study Parkinson's disease in the lab

Nov 15 2023University of Arizona Health SciencesA recent study published inProgress in Neurobiologyand led by researchers at the University of Arizona College of Medicine – Tucson has deve
World medicine November 24,2023
Scientists develop an improved method to study Parkinson's disease in the lab

Scientists develop an improved method to study Parkinson's disease in the lab

Nov 15 2023University of Arizona Health SciencesA recent study published inProgress in Neurobiologyand led by researchers at the University of Arizona College of Medicine – Tucson has deve
World medicine November 24,2023
Cancer stem cells induce macrophage aging, creating conditions for tumor formation

Cancer stem cells induce macrophage aging, creating conditions for tumor formation

Nov 14 2023Hokkaido UniversityCancer stem cells cause the aging of macrophages in mice with healthy immune systems, creating conditions for the formation of tumors.Cancerous tumors consist of a mixtur
World medicine November 24,2023
Cancer stem cells induce macrophage aging, creating conditions for tumor formation

Cancer stem cells induce macrophage aging, creating conditions for tumor formation

Nov 14 2023Hokkaido UniversityCancer stem cells cause the aging of macrophages in mice with healthy immune systems, creating conditions for the formation of tumors.Cancerous tumors consist of a mixtur
World medicine November 24,2023
ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC

ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC

August 11, 2023Megan HollaschYasser Mohamed Ali Ged, MBBS, highlights the early efficacy seen in patients with renal cell carcinoma with BAP1 mutations and next steps for the ORCHID trial.Yasser Moham
World medicine November 24,2023
ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC

ORCHID Trial of Olaparib Monotherapy Could Lay Groundwork for Investigating PARP Inhibitors in Advanced RCC

August 11, 2023Megan HollaschYasser Mohamed Ali Ged, MBBS, highlights the early efficacy seen in patients with renal cell carcinoma with BAP1 mutations and next steps for the ORCHID trial.Yasser Moham
World medicine November 24,2023
NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

July 27, 2023Kristi RosaThe allogeneic natural killer cell therapy NKX019 was found to have an acceptable toxicity profile and to induce deep and durable responses in patients with relapsed or refract
World medicine November 24,2023
NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

July 27, 2023Kristi RosaThe allogeneic natural killer cell therapy NKX019 was found to have an acceptable toxicity profile and to induce deep and durable responses in patients with relapsed or refract
World medicine November 24,2023
Tumor-immune interactions predict treatment responses in multiple myeloma

Tumor-immune interactions predict treatment responses in multiple myeloma

Nov 9 2023Sylvester Comprehensive Cancer CenterA multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactio
World medicine November 24,2023
Tumor-immune interactions predict treatment responses in multiple myeloma

Tumor-immune interactions predict treatment responses in multiple myeloma

Nov 9 2023Sylvester Comprehensive Cancer CenterA multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactio
World medicine November 24,2023
Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

August 10, 2023Ashling WahnerHans Lee, MD,discusses unmet needs in patients with relapsed/refractory multiple myeloma, highlights key efficacy and safety findings from the LINKER-MM1 trial, and
World medicine November 24,2023
Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

August 10, 2023Ashling WahnerHans Lee, MD,discusses unmet needs in patients with relapsed/refractory multiple myeloma, highlights key efficacy and safety findings from the LINKER-MM1 trial, and
World medicine November 24,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com